Interaction of benzylidene-anabaseine analogues with agonist and allosteric sites on muscle nicotinic acetylcholine receptors

British Journal of Pharmacology

Volumn 157, Issue 2, 2009, Pages 320-330

  Arias, H R ^a,d   Xing, H ^b   MacDougall, K ^b   Blanton, M P ^c   Soti, F ^b   Kern, W R ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

Author keywords

40H DMXBA; 40H GTS 21; Benzylidlne anabaselne; DMXBA; GTS 21; Nicotinic acetylcholine receptor; Non competitive antagonist; Partial agonist; PCP

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (4 HYDROXY 2 METHOXYBENZYLIDENE)ANABASEINE; ACETYLCHOLINE; AMOBARBITAL; BENZYLIDENE DERIVATIVE; BUNGAROTOXIN RECEPTOR; DIZOCILPINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; TETRACAINE; UNCLASSIFIED DRUG; ANABASEINE; ANABASINE; DRUG DERIVATIVE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; ANIMAL; CELL CULTURE; METABOLISM; MUSCLE; RADIOASSAY; TORPEDO;

ALLOSTERIC SITE; ANABASINE; ANIMALS; BENZYLIDENE COMPOUNDS; CELLS, CULTURED; HUMANS; MUSCLES; NICOTINIC AGONISTS; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC; TORPEDO;

EID: 68549092587     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00156.x     Document Type: Article

References (45)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Arias HR (1996). Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor. J. Neurosci Res 44: 97-105. (Pubitemid 26134400)
3. Arias HR (2006). Ligand-gated ion channel receptor superfamilies. In: Arias HR (ed.). Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor Superfamilies. Research Signpost: Kerala, India, pp. 1-25.
4. Arias HR, Bhumireddy P (2005). Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci 6: 451-472.
5. Arias HR, McCardy EA, Blanton MP (2001a). Characterization of the dizocilpine binding site on the nicotinic acetylcholine receptor. Mol Pharmacol 59: 1051-1060. (Pubitemid 32381584)
6. Arias HR, McCardy EA, Gallagher MJ, Blanton MB (2001b). Interaction of barbiturate analogs with the Torpedo californica nicotinic acetylcholine receptor ion channel. Mol Pharmacol 60: 497-506.
7. Arias HR, Kern WR, Trudell JR, Blanton MP (2002a). Unique general anesthetic binding sites within distinct conformational states of the nicotinic acetylcholine receptor. Int Rev Neurobiol 54: 1-50. (Pubitemid 44943686)
8. Arias HR, McCardy EA, Bayer EZ, Gallagher MJ, Blanton MB (2002b). Allosterically linked noncompetitive antagonist binding sites in the resting nicotinic acetylcholine receptor ion channel. Arch Biochem Biophys 403: 121-131.
9. Arias HR, Trudell JR, Bayer EZ, Hester B, McCardy EA, Blanton MB (2003). Noncompetitive antagonist binding sites in the Torpedo nicotinic acetylcholine receptor ion channel. Structure-activity relationship studies using adamantane derivatives. Biochemistry 42: 7358-7370. (Pubitemid 36735814)
10. Arias HR, Bhumireddy P, Spitzmaul G, Trudell JR, Bouzat C (2006a). Molecular mechanisms and binding site location for the noncompetitive antagonist crystal violet on nicotinic acetylcholine receptors. Biochemistry 45: 2014-2026. (Pubitemid 43271301)
11. Arias HR, Bhumireddy P, Bouzat C (2006b). Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int J Biochem Cell Biol 38: 1254-1276. (Pubitemid 43271301)
12. Azuma R, Komuro H, Korsch BH, Andre JC, Onnagawa O, Black SR et al. (1999). Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. Xenobiot 29: 747-762. (Pubitemid 29371092)
13. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes so percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
14. 125I-αbungarotoxin receptor subtypes. Mol Pharmacol 47: 164-171.
15. Fletcher GH, Steinbach JH (1996). Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors. Mol Pharmacol 49: 938-947.
16. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Kem WR et al. (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. J. Gen Psychiat 165: 1040-1047.
17. 3H]tetracaine. Mol Pharmacol 56: 300-307.
18. Gallagher MJ, Chiara DC, Cohen JB (2001). Interactions between 3-(trifluoromethyl)-3-(m-[(125)I]iodophenyl)diazirine and tetracaine, phencyclidine, or histrionicotoxin in the Torpedo species nicotinic acetylcholine receptor ion channel. Mol Pharmacol 59: 1514-1522.
19. Horváth LI, Arias HR, Hankovszky HO, Hideg K, Barrantes FJ, Marsh D (1990). Association of spin-labeled local anesthetics at the hydrophobic surface of acetylcholine receptor in native membranes from Torpedo marmorata. Biochemistry 29: 8707-8713. (Pubitemid 20302765)
20. Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K et al. (2007). Muscle and neuronal nicotinic acetylcholine receptors: structure, function and pathogenicity. FEBS J 274: 3799-3845. (Pubitemid 47087687)
21. Kern WR, Mahnir VM, Papke R, Lingle C (1997). Anabaseine is a potent agonist upon muscle and neuronal alpha-bungarotoxin sensitive nicotinic receptors. J Pharmacol Exp Ther 283: 979-992. (Pubitemid 28016467)
22. Kem WR, Mahnir VM, Prokai L, Papke RL, Cao X, LeFrancois S et al. (2004). Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS21): Their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol 65: 56-67. (Pubitemid 38113886)
23. Kem WR, Soti F, LeFrancois S, Wildeboer K, MacDougall K, Wei D et al (2006). The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): chemical and pharmacological properties. Marine Drugs (Marine Toxins and Ion Channels) 4: 255-273. (Pubitemid 43763915)
24. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE et al. (2003). Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28: 542-551.
25. Kopta C, Steinbach JH (1994). Comparison of mammalian adult and fetal nicotinic acetylcholine receptors stably expressed in fibroblasts. J Neurosci 14: 3922-3933. (Pubitemid 24174134)
26. Lee ST, Wildeboer K, Panter KE, KemDips WR, Gardner DR, Molyneux RJ et al. (2006). Relative toxicities and neuromuscular nicotinic receptor agonistic potencies of anabasine enantiomers and anabaseine. Neurotoxicol Teratol 28: 220-228.
27. Mahnir VM, Lin B, Prokai-Tatrai K, Kem WR (1998). Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition. Biopharm Drug Disp 19: 147-151. (Pubitemid 28152287)
28. Mantipragada SB, Horváth LI, Arias HR, Schwarzmann G, Sandhoff K, Barrantes FJ, Marsh D (2003). Lipid-protein interactions and the effect of local anesthetics in acetylcholine receptor-rich membranes from Torpedo marmorata electric organ. Biochemistry 42: 91679175. (Pubitemid 36935426)
29. Meyer EM, Tay ET, Papke RL, Meyers C, Huang GL, de Fiebre CM (1997). 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 768: 49-56. (Pubitemid 27433476)
30. Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL (1998). Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat α7 nicotinic receptors. J Pharm Exp Ther 287: 918-925. (Pubitemid 29131601)
31. Middleton RE, Cohen JB (1991). Mapping of the acetylcholine binding site of the nicotinic acetylcholine receptor: [3H]nicotine as an agonist photoaffinity label. Biochemistry 30: 6987-6997.
32. 3H]tetracaine, a nondesensitizing noncompetitive antagonist. Mol Pharmacol 56: 290299.
33. Moore MA, McCarthy MP (1995). Snake venom toxins, unlike smaller antagonists, appear to stabilize a resting state conformation of the nicotinic acetylcholine receptor. Biochim Biophys Acta 1235: 336342.
34. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al. (2006). Proof-of-concept trial of an α7-nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638. (Pubitemid 43848294)
35. Pagan OR, Eterovic VA, Garcia M, Vergne D, Basilio CM, Rodriguez AD et al. (2001). Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction. Biochemistry 40: 11121-11130. (Pubitemid 32847980)
36. Papke RL (2002). Enhanced inhibition of a mutant neuronal nicotinic acetylcholine receptor by agonists: protection of function by (E)-Nmethyl-4-(3-pyridinyl)-3-butene-l-amine (TC-2403). J Pharm Exp Ther 301: 765-773.
37. Papke RL, Thinschmidt JS (1998). The correction of α7 nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes. Neurosci Lett 256: 163-166. (Pubitemid 28546915)
38. Papke RL, Meyer E, Nutter T, Uteshev VV (2000). α7 Receptor-selective agonists and modes of α7 receptor activation. Eur J Pharmacol 393: 179-195. (Pubitemid 30193415)
39. Papke RL, Meyer EM, Lavieri S, Bollampally SR, Papke TA, Horenstein NA et al (2004). Effects at a distance in α7 nAChR selective agonists: benzylidene substitutions that regulate potency and efficacy. Neuropharmacology 46: 1023-1038. (Pubitemid 38471956)
40. 3H]ethidium diazide within the Torpedo nicotinic acetylcholine receptor ion channel. Biochemistry 39: 11452-11462.
41. Pedersen SE, Dreyer EB, Cohen JB (1986). Location of ligand-binding sites on the nicotinic acetylcholine receptor α-subunit. J Biol Chem 261: 13735-13743. (Pubitemid 17196398)
42. Schild HO (1949). pAx and competitive drug antagonism. Br J Pharmacol 4: 277-280.
43. Uteshev VV, Meyer EM, Papke RL (2002). Activation and inhibition of native neuronal α-bungarotoxin-sensitive nicotinic ACh receptors. Brain Res 948: 33-46. (Pubitemid 35283759)
44. Uteshev W, Meyer EM, Papke RL (2003). Regulation of neuronal function by choline and 40H-GTS-21 through α7 nicotinic receptors. J Neurophysiol 89: 1797-1806. (Pubitemid 36444236)
45. Ziskind L, Dennis MJ (1978). Depolarizing effect of curare on embryonic rat muscles. Nature 276: 622-623. (Pubitemid 9087767)